Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: OPN001
MIFTS: 51

Open-Angle Glaucoma

Categories: Eye diseases, Genetic diseases, Rare diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Open-Angle Glaucoma

About this section

MalaCards integrated aliases for Open-Angle Glaucoma:

Name: Open-Angle Glaucoma 12 15
Glaucoma, Open-Angle 44 73
Open Angle Glaucoma 12
Pigmentary Glaucoma 12
Wide-Angle Glaucoma 12
Glaucoma Open-Angle 55
Glaucoma Simplex 12

Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases
Anatomical: Eye diseases
See all MalaCards categories (disease lists)
ICD10: 33


External Ids:

Disease Ontology 12 DOID:1067
MeSH 44 D005902
NCIt 50 C34641
UMLS 73 C0017612
Sources

Summaries for Open-Angle Glaucoma

About this section
Disease Ontology : 12 A glaucoma characterized by optic nerve damage resulting in progressive loss of visual field and increased pressure in the eye due to trabecular blockage.

MalaCards based summary : Open-Angle Glaucoma, also known as glaucoma, open-angle, is related to glaucoma 1, open angle, a and ocular hypertension. An important gene associated with Open-Angle Glaucoma is MYOC (Myocilin), and among its related pathways/superpathways are Degradation of the extracellular matrix and Fluid shear stress and atherosclerosis. The drugs Ephedrine and Latanoprost have been mentioned in the context of this disorder. Affiliated tissues include eye, testes and endothelial.

Sources

Related Diseases for Open-Angle Glaucoma

About this section

Diseases in the Open-Angle Glaucoma family:

Glaucoma 1, Open Angle, a Glaucoma, Primary Open Angle
Glaucoma 1, Open Angle, P Glaucoma 1, Open Angle, I

Diseases related to Open-Angle Glaucoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 135)
# Related Disease Score Top Affiliating Genes
1 glaucoma 1, open angle, a 34.5 CYP1B1 MYOC OPTN
2 ocular hypertension 32.7 MYOC OPTN TMCO1
3 exfoliation syndrome 32.4 ELN LOXL1 MMP1
4 intraocular pressure quantitative trait locus 32.3 CDKN2B-AS1 CYP1B1 LOXL1 MYOC OPTN WDR36
5 primary angle-closure glaucoma 32.1 CYP1B1 MYOC OPTN
6 glaucoma 3, primary infantile, b 31.8 CYP1B1 LTBP2
7 glaucoma, normal tension 31.5 LOXL1 OPTN
8 glaucoma 3, primary congenital, a 31.3 CYP1B1 LTBP2 MYOC OPTN
9 optic nerve disease 31.1 ELN MYOC OPTN
10 primary congenital glaucoma 31.1 CYP1B1 LTBP2 MYOC OPTN WDR36
11 low tension glaucoma 31.1 CDKN2B-AS1 MYOC OPTN TBK1 WDR36
12 glaucoma-related pigment dispersion syndrome 31.0 CYP1B1 LOXL1
13 chronic closed-angle glaucoma 31.0 OPTN TGFB2
14 glaucoma, primary open angle 30.6 ASB10 CAV2 CDKN2B-AS1 CYP1B1 ELN GSTM1
15 neovascular glaucoma 30.1 OPTN TGFB2
16 juvenile glaucoma 28.9 CYP1B1 ELN MYOC NTF4 OPTN TGFB2
17 residual stage of open angle glaucoma 12.4
18 glaucoma 1, open angle, f 12.2
19 glaucoma 1, open angle, p 12.0
20 glaucoma 1, open angle, g 11.9
21 glaucoma 1, open angle, o 11.9
22 glaucoma 1, open angle, d 11.5
23 glaucoma 1, primary open angle, c 11.3
24 acrofrontofacionasal dysostosis 10.9 CYP1B1 OPTN
25 hydrophthalmos 10.8 CYP1B1 LTBP2 OPTN
26 axenfeld-rieger syndrome, type 2 10.7 ASB10 OPTN
27 retinitis 10.7
28 hearing loss, noise-induced 10.7 GSTM1 GSTT1
29 early-onset glaucoma 10.7 CYP1B1 MYOC
30 sister chromatid exchange, frequency of 10.6 GSTM1 GSTT1
31 excessive tearing 10.6 CYP1B1 LTBP2 MYOC OPTN
32 megalocornea 10.5 LTBP2 OPTN
33 cataract 10.5
34 isolated cleft lip 10.5 GSTM1 GSTT1
35 myopia 10.4
36 aging 10.4
37 neuropathy 10.4
38 choroiditis 10.4
39 acute lymphocytic leukemia 10.4 CDKN2B-AS1 GSTM1 GSTT1
40 endotheliitis 10.4
41 ischemic optic neuropathy 10.3
42 helicobacter pylori infection 10.3
43 ocular hypotension 10.3
44 alzheimer disease 10.2
45 nonarteritic anterior ischemic optic neuropathy 10.2
46 retinal vein occlusion 10.2
47 cerebritis 10.2
48 corneal edema 10.2 CYP1B1 LTBP2 MMP1 MYOC OPTN
49 chronic actinic dermatitis 10.2 ELN MMP1
50 macular degeneration, age-related, 1 10.2

Comorbidity relations with Open-Angle Glaucoma via Phenotypic Disease Network (PDN):


Anatomical Narrow Angle Borderline Glaucoma Glaucoma, Primary Open Angle
Hypertension, Essential Ocular Hypotension

Graphical network of the top 20 diseases related to Open-Angle Glaucoma:



Diseases related to Open-Angle Glaucoma
Sources

Symptoms & Phenotypes for Open-Angle Glaucoma

About this section
Sources

Drugs & Therapeutics for Open-Angle Glaucoma

About this section

Drugs for Open-Angle Glaucoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 206)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ephedrine Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 299-42-3 9294
2
Latanoprost Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 130209-82-4 5282380 5311221
3
Pseudoephedrine Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 90-82-4 7028
4
Travoprost Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 157283-68-6 5282226
5
Bimatoprost Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 155206-00-1 5311027
6
Dorzolamide Approved Phase 4,Phase 3,Phase 2,Not Applicable 120279-96-1 3154 5284549
7
Timolol Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 26839-75-8 33624 5478
8
Ketorolac Approved Phase 4,Not Applicable 74103-06-3, 66635-83-4 3826
9
Brinzolamide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 138890-62-7 68844
10
Apraclonidine Approved Phase 4,Not Applicable 66711-21-5 2216
11
Sorbitol Approved Phase 4 50-70-4 5780
12
Pilocarpine Approved, Investigational Phase 4,Not Applicable 54-71-7, 92-13-7 5910
13
Dipivefrin Approved Phase 4,Phase 3 52365-63-6 3105
14
Fluticasone Approved, Experimental, Investigational Phase 4 90566-53-3 62924
15
Bevacizumab Approved, Investigational Phase 4,Not Applicable 216974-75-3
16
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
17
Loteprednol Approved Phase 4 82034-46-6, 129260-79-3 444025 9865442
18
Tobramycin Approved, Investigational Phase 4 32986-56-4 5496 36294
19
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
20
Maleic acid Experimental Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 110-16-7 444266
21 Antihypertensive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
22 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
23 Nasal Decongestants Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
24 Ophthalmic Solutions Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
25 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
26 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
27 Respiratory System Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
28 Tetrahydrozoline Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
29 Vasoconstrictor Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
30 Adrenergic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
31 Adrenergic Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
32 Adrenergic beta-Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
33 Anti-Arrhythmia Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
34 Carbonic Anhydrase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
35 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
36 Ketorolac Tromethamine Phase 4,Not Applicable
37 Brimonidine Tartrate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 70359-46-5
38 Adrenergic Agonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
39 Adrenergic alpha-2 Receptor Agonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
40 Adrenergic alpha-Agonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
41 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Not Applicable
42 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Not Applicable
43 Mitomycins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
44 Anesthetics Phase 4,Phase 1,Phase 2
45 Alkylating Agents Phase 4,Phase 3,Phase 2,Not Applicable
46 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
47 Lubricant Eye Drops Phase 4,Phase 3,Phase 2,Not Applicable
48 Anti-Infective Agents Phase 4,Phase 2,Not Applicable
49 Anti-Infective Agents, Local Phase 4,Phase 2
50 Benzalkonium Compounds Phase 4,Phase 2

Interventional clinical trials:

(show top 50) (show all 701)
# Name Status NCT ID Phase Drugs
1 A Study of the Glaukos Trabecular Micro-bypass Stent in Open Angle Glaucoma Subjects 1 Stent Versus 2 Unknown status NCT00326079 Phase 4
2 Evaluation of the XEN Implant in Moderate POAG Subjects Unknown status NCT02006693 Phase 4
3 The Impact of Topical Prostaglandins on the Biomechanical Properties of the Cornea in Patients With Open Angle Glaucoma Unknown status NCT02388360 Phase 4 topical prostaglandin analogs
4 Efficacy and Safety of Three Different Latanoprost 0,005% Eyedrops in Subjects Affected by Primary Open Angle Glaucoma Unknown status NCT01580254 Phase 4 IOPIZE© Latanoprost eyedrops;GALAXIA© Latanoprost eyedrops;Latanoprost RATIOPHARM© latanoprost eyedrops
5 PASCAL Trabeculoplasty Unknown status NCT00804323 Phase 4
6 Generic Travoprost Versus Brand Name Travoprost in Patients With Primary Open Angle Glaucoma or Ocular Hypertension Unknown status NCT02796560 Phase 4 Brand name travoprost;Generic travoprost
7 Safety and Efficacy Assessment of Monoprost® in Comparison With Lumigan® 0.01 % and Lumigan® 0.03% Unit Dose Unknown status NCT02017327 Phase 4 Monoprost;Lumigan 0.01%;Lumigan 0.03% Unit Dose
8 Prospective, Randomized, Controlled Study to Assess Efficacy,Safety, and Tolerability of SLT vs. PLT in Patients With POAG Unknown status NCT02231515 Phase 4
9 Impact of Timolol/Dorzolamide Therapy on Autoregulation in Glaucoma Patients Unknown status NCT02053298 Phase 4 Timolol & Dorzolamide
10 The Laser in Pseudoexfoliation (LIP) Study Unknown status NCT01704989 Phase 4 Prostagladin
11 Comparison of Silicone and Porous Plate Ahmed Glaucoma Valves Unknown status NCT01883856 Phase 4
12 Comparison of the Ahmed Glaucoma Valve FP7 and FP8 in Pediatric Glaucoma Unknown status NCT01494974 Phase 4
13 Micropulse Laser Trabeculoplasty (MLT) Versus Selective Laser Trabeculoplasty (SLT) for Treatment of Open Angle Glaucoma Completed NCT01956942 Phase 4
14 An Open, Non-randomized Pilot Study on the Effect of Preservative Free Tafluprost (Saflutan® Augentropfen) in Patients With Ocular Hypertension or Primary Open Angle Glaucoma With an Uncontrolled Intraocular Pressure of 30 mmHg and More Completed NCT01979913 Phase 4 Saflutan® 15 microgram/ml Augentropfen im Einzeldosisbehältnis
15 Subjects With Open-angle Glaucoma, Pseudoexfoliative Glaucoma, or Ocular Hypertension Naïve to Medical and Surgical Therapy, Treated With Two Trabecular Micro-bypass Stents (iStent)or Travoprost Completed NCT01443988 Phase 4 Travoprost
16 Prospective Evaluation of Open-angle Glaucoma Subjects on Two Topical Hypotensive Medication Treated With Two iStents Completed NCT01252888 Phase 4
17 A Study of the Glaukos Trabecular Micro-Bypass Stent in Refractory Open Angle Glaucoma Subjects Completed NCT00326040 Phase 4
18 A Study of the Trabecular Micro-Bypass Stent in Combination With Cataract Surgery in Open Angle Glaucoma Subjects. Completed NCT00326014 Phase 4
19 Prospective Evaluation of Open-Angle Glaucoma Subjects on One Topical Hypotensive Medication Treated With Two iStents Completed NCT01252862 Phase 4
20 24-hour Intraocular Pressure (IOP) Control With Dorzolamide/Timolol and Latanoprost/Timolol Fixed Combination in Open-angle Glaucoma Completed NCT00397241 Phase 4 Drug: dorzolamide/timolol;Drug: latanoprost/timolol;dorzolamide/timolol and latanoprost;placebo (artificial tears)
21 Assessment of Intraocular Pressure (IOP) Control in Subjects With Open-Angle Glaucoma or Ocular Hypertension Treated With Travoprost 0.004% (TRAVATAN® Z) or Bimatoprost 0.01% (LUMIGAN®) Completed NCT01464424 Phase 4 Travoprost 0.004% ophthalmic solution;Bimatoprost 0.01% ophthalmic solution
22 Dry Eye Study With Cosopt® Over 8 Weeks in Patients With Open-Angle Glaucoma or Ocular Hypertension (0507A-152)(COMPLETED) Completed NCT00545064 Phase 4 dorzolamide hydrochloride (+) timolol maleate
23 Efficacy and Tolerability of an Innovative Formulation of BAK-free Latanoprost Completed NCT03331770 Phase 4 Latanoprost Ophthalmic Product
24 Phase IV Randomised Double-masked Clinical Trial: Assessing Morning Versus Evening Dosing of a Fixed Dose Combination of Travoprost 0.004% / Timolol Maleate 0.5% in Patients With Primary Open-angle Glaucoma or Ocular Hypertension Completed NCT00759239 Phase 4 Travoprost 0.004% / Timolol maleate 0.5%;Travoprost 0.004% / Timolol maleate 0.5%
25 Latanoprost Versus Tafluprost: 24-hour Intraocular Pressure (IOP) Completed NCT01162603 Phase 4 TAFLUPROST 0.0015% EYEDROPS;LATANOPROST 0.005% EYEDROPS
26 A Prospective, Unmasked Evaluation of the iStent in Patients With Primary Open-Angle Glaucoma Completed NCT00911924 Phase 4
27 Evaluation of the iStent Versus Two Ocular Hypotensive Agents in Patients With Primary Open-angle Glaucoma (POAG) Completed NCT00913029 Phase 4 latanoprost/timolol
28 A Single Dose Comfort Comparison of Travatan Z in One Eye Versus Xalatan in the Opposite Eye in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension Completed NCT00527592 Phase 4 Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®);Latanoprost ophthalmic solution 0.005% (XALATAN®)
29 A 12 Week Comparison of DuoTrav and Xalacom in Open-Angle Glaucoma Completed NCT00887029 Phase 4 DuoTrav (travoprost-timolol ophthalmic drops);Xalacom (latanoprost-timolol ophthalmic drops)
30 Comparison of Intraocular Pressure (IOP)-Lowering Efficacy and Safety of AZORGA® Ophthalmic Suspension and COSOPT® Ophthalmic Solution Completed NCT02325518 Phase 4 Brinzolamide 1%/Timolol maleate 0.5% fixed combination ophthalmic suspension;Dorzolamide hydrochloride 1%/Timolol maleate 0.5% ophthalmic solution;Subject's habitual PGA monotherapy
31 Evaluation of Intraocular Pressure Using Simbrinzaâ„¢ in Patients With Open-Angle Glaucoma or Ocular Hypertension Completed NCT01978600 Phase 4 Brinzolamide 1%/Brimonidine 0.2% ophthalmic suspension;Timolol Maleate 0.5%
32 Comparison of Istalolâ„¢ 0.5% QD (Timolol Maleate/Sorbitol Complex, ISTA Pharmaceutical) to Brimonidine Tartrate 0.1% BID as Adjunctive Therapy to Latanoprost 0.005% in Adults With Ocular Hypertension (OHT) or Open-Angle Glaucoma (OAG) Completed NCT00698945 Phase 4 Istalol and Optive;Alphagan
33 Safety of GANFORT® Ophthalmic Solution in Chinese Patients With Open-angle Glaucoma or Ocular Hypertension Completed NCT02571712 Phase 4 bimatoprost 0.03% plus timolol 0.5%
34 Efficacy and Safety of Travoprost 0.004% Versus Tafluprost 0.0015% in Patients With Primary Open-angle Glaucoma or Ocular Hypertension Completed NCT00966940 Phase 4 Travoprost 0.004% ophthalmic solution (TRAVATAN);Tafluprost 0.0015% ophthalmic solution
35 Comparison of Ex-PRESSTM Mini Glaucoma Shunt to Trabeculectomy in Subjects With Open Angle Glaucoma Completed NCT00444080 Phase 4
36 Travatan Versus Timoptic in Treating Open-angle Glaucoma or Ocular Hypertension Completed NCT00763061 Phase 4 Travoprost 0.004% Ophthalmic Solution (Travatan);Timolol 0.5% Ophthalmic Solution (Timoptic)
37 Examination of Ocular Surface Effects With Administration of Travatan Z and XALATAN Completed NCT00798759 Phase 4 Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®);Latanoprost ophthalmic solution 0.005% (XALATAN®)
38 Study of Brinzolamide and Timolol When Added to Travoprost in Primary Open-angle Glaucoma or Ocular Hypertension Completed NCT00372827 Phase 4 Brinzolamide 1% added to Travoprost 0.004%
39 A Study to Assess the Efficacy of 3 Months of Latanoprost Treatment in Reducing the Intraocular Pressure in Patients With Ocular Hypertension or Open-Angle Glaucoma Completed NCT00647101 Phase 4 Latanoprost
40 Comparison of the Fixed Combinations of Brimonidine/Timolol and Dorzolamide/Timolol in Subjects With Open-Angle Glaucoma or Ocular Hypertension Completed NCT00822081 Phase 4 brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination;dorzolamide hcl 2%/ timolol maleate 0.5% fixed combination;brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination as adjunctive to current prostaglandin therapy.;dorzolamide hcl 2%/timolol maleate 0.5% fixed combinatin as adjunctive to current prostaglandin therapy.
41 Comparison of the Fixed Combinations of Brimonidine/Timolol and Dorzolamide/Timolol in Subjects With Open-Angle Glaucoma or Ocular Hypertension Completed NCT00822055 Phase 4 brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination;dorzolamide hcl 2%/timolol maleate 0.5% fixed combination;brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination as adjunctive to current prostaglandin therapy;dorzolamide hcl 2%/timolol maleate 0.5% fixed combination as adjunctive to current prostaglandin therapy
42 Comparison Of Trabeculectomy Versus The Ex-PRESS Miniature Glaucoma Device In The Same Patient: A Prospective Randomized Study Completed NCT00698438 Phase 4
43 Efficacy And Safety of Pneumatic Trabeculoplasty Completed NCT01540331 Phase 4
44 Laser-1st vs Drops-1st for Glaucoma and Ocular Hypertension Completed NCT03395535 Phase 4 Primary Medical Treatment Pathway
45 Patient Satisfaction With Timolol in Subjects With Open-Angle Glaucoma or Ocular Hypertension Completed NCT00804648 Phase 4 Timolol Maleate in Sorbate;Timolol hemihydrate;Timolol maleate gel forming solution
46 Efficacy of Travoprost/Timolol for Uncontrolled Intraocular Pressure Completed NCT02003391 Phase 4 Beta-blocker monotherapy;Travoprost 0.004% / timolol 0.5% fixed combination ophthalmic solution
47 Efficacy And Safety Of Xalatan Compared To Usual Care In Patients With Open Angle Glaucoma Or Ocular Hypertension. Completed NCT00140062 Phase 4 latanoprost 0.005% (Xalatan)
48 Blood-aqueous Barrier Changes After the Use of Timolol and Prostaglandin Analogues Fixed Combination in Pseudophakic Patients With POAG Completed NCT01978015 Phase 4 travoprost and timolol maleate fixed combination;latanoprost and maleate timolol fixed combination;bimatoprost and timolol maleate fixed combination;dextran and hypromellose
49 24-hr Intraocular Pressure Control With Dorzolamide/Timolol vs the Brimonidine/Timolol Fixed Combination Completed NCT00972257 Phase 4 treatment with dorzolamide/timolol;treatment with brimonidine/timolol
50 Safety and Efficacy of Changing to DuoTrav in Patients Uncontrolled on Timolol Completed NCT01336569 Phase 4 Travoprost 0.004%/timolol maleate 0.5% fixed combination

Search NIH Clinical Center for Open-Angle Glaucoma

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: glaucoma, open-angle

Sources

Genetic Tests for Open-Angle Glaucoma

About this section
Sources

Anatomical Context for Open-Angle Glaucoma

About this section

MalaCards organs/tissues related to Open-Angle Glaucoma:

41
Eye, Testes, Endothelial, Brain, Cortex, Retina, Bone
Sources

Publications for Open-Angle Glaucoma

About this section

Articles related to Open-Angle Glaucoma:

(show top 50) (show all 1481)
# Title Authors Year
1
Association of catalase polymorphisms with primary open-angle glaucoma in a Chinese population. ( 28829657 )
2018
2
Systemic Medication Associations with Presumed Advanced or Uncontrolled Primary Open-Angle Glaucoma. ( 29433851 )
2018
3
Are we ready for genetic testing for primary open-angle glaucoma? ( 29379103 )
2018
4
The Efficacy of Transcorneal Electrical Stimulation for the Treatment of Primary Open-angle Glaucoma: A Pilot Study. ( 29415904 )
2018
5
Proteomic Analysis of Aqueous Humor from Primary Open Angle Glaucoma Patients on Drug Treatment Revealed Altered Complement Activation Cascade. ( 29901396 )
2018
6
Incidence of retinal vein occlusion in open-angle glaucoma: a nationwide, population-based study using the Korean Health Insurance Review and Assessment Database. ( 29360215 )
2018
7
Analysis combining correlated glaucoma traits identifies five new risk loci for open-angle glaucoma. ( 29449654 )
2018
8
Case of Ab Interno Trabeculectomy in Juvenile Open-angle Glaucoma with 5-year Follow-up. ( 29426460 )
2018
9
Correction to: Latanoprostene Bunod Ophthalmic Solution 0.024%: A Review in Open-Angle Glaucoma and Ocular Hypertension. ( 29846910 )
2018
10
Alzheimer's disease and primary open-angle glaucoma associated with vascular health in patients of African descent. ( 29855159 )
2018
11
Carbohydrate ingestion induces differential autonomic dysregulation in normal-tension glaucoma and primary open angle glaucoma. ( 29879162 )
2018
12
A new diagnostic model of primary open angle glaucoma based on FD-OCT parameters. ( 29977806 )
2018
13
Discontinuation of the herbal preparation <i>Hypericum perforatum</i>, also known as St John's wort, associated with improved intraocular pressure control in a patient on topical beta-blockers for primary open-angle glaucoma. ( 29930462 )
2018
14
Correction to: The Effect of Posture on Intraocular Pressure and Systemic Hemodynamic Parameters in Treated and Untreated Patients with Primary Open-Angle Glaucoma, by Katsanos, A., Dastiridou, A.I., Quaranta, L., Rulli, E., Riva, I., Dimasi, V., Tsironi, E.E., and Weinreb, R.N. J Ocul Pharmacol Ther 2017;33(8):598-603. DOI: 10.1089/jop.2017.0030. ( 29393727 )
2018
15
A Schlemm Canal Microstent for Intraocular Pressure Reduction in Primary Open-Angle Glaucoma and Cataract: The HORIZON Study. ( 29945799 )
2018
16
Progression of Primary Open Angle Glaucoma in Diabetic and Non-diabetic Patients. ( 29447914 )
2018
17
The effect of trabeculectomy on serum brain-derived neurotrophic factor levels in primary open-angle glaucoma. ( 29417213 )
2018
18
Reduced Cerebral Blood Flow in the Visual Cortex and Its Correlation with Glaucomatous Structural Damage to the Retina in Patients with Mild to Moderate Primary Open Angle Glaucoma. ( 29952821 )
2018
19
Comparison of total/active ghrelin levels in primary open angle glaucoma, pseudoexfoliation glaucoma and pseudoexfoliation syndrome. ( 29862183 )
2018
20
Selective laser trabeculoplasty for primary open-angle glaucoma patients younger than 40 years. ( 29426447 )
2018
21
The relationship between HDAC6, CXCR3, and SIRT1 genes expression levels with progression of primary open-angle glaucoma. ( 29384425 )
2018
22
Multicenter, Randomized, Controlled Study Comparing Tafluprost/Timolol Fixed Combination with Latanoprost/Timolol Fixed Combination in Primary Open-Angle Glaucoma and Ocular Hypertension. ( 29873009 )
2018
23
Simplifying &amp;quot;target&amp;quot; intraocular pressure for different stages of primary open-angle glaucoma and primary angle-closure glaucoma. ( 29582808 )
2018
24
Identification and genotype phenotype correlation of novel mutations in SIX6 gene in primary open angle glaucoma. ( 29405792 )
2018
25
Reduction of Intraocular Pressure by Additional Trabeculotomy Ab Externo in Eyes with Primary Open-angle Glaucoma. ( 29916998 )
2018
26
Genome-wide association study identifies seven novel susceptibility loci for primary open-angle glaucoma. ( 29452408 )
2018
27
Increased risk of open-angle glaucoma among patients with diabetes mellitus: a 10-year follow-up nationwide cohort study. ( 29862632 )
2018
28
Visual Disability among Juvenile Open Angle Glaucoma Patients. ( 29394204 )
2018
29
Comparison of optical coherence tomography findings and visual field changes in patients with primary open-angle glaucoma and amyotrophic lateral sclerosis. ( 29169899 )
2018
30
Clinical outcomes of patterned laser trabeculoplasty as adjuvant therapy in open angle glaucoma and ocular hypertension. ( 29675383 )
2018
31
Differentially expressed microRNAs in the aqueous humor of patients with exfoliation glaucoma or primary open-angle glaucoma. ( 29401312 )
2018
32
Juvenile Open Angle Glaucoma with Non Bullous Congenital Ichthyosiform Erythroderma. ( 29952820 )
2018
33
Application of Bayes' to the prediction of referral decisions made by specialist optometrists in relation to chronic open angle glaucoma. ( 29422665 )
2018
34
Noninvasive Detection of Mitochondrial Dysfunction in Ocular Hypertension and Primary Open-angle Glaucoma. ( 29750714 )
2018
35
Differentiating Occult Branch Retinal Artery Occlusion from Primary Open-angle Glaucoma. ( 29370018 )
2018
36
Pediatric Multiple Endocrine Neoplasia Type 2B: Clinicopathological Correlation of Perilimbal Mucosal Neuromas and Treatment of Secondary Open-Angle Glaucoma. ( 29765955 )
2018
37
The risk of primary open angle glaucoma following vitreoretinal surgery- a population-based study. ( 29940165 )
2018
38
Non-penetrating glaucoma surgery for advanced open-angle glaucoma. ( 29911272 )
2018
39
Pattern of peripapillary capillary density loss in ischemic optic neuropathy compared to that in primary open-angle glaucoma. ( 29320503 )
2018
40
Long-term titrated IOP control with one, two, or three trabecular micro-bypass stents in open-angle glaucoma subjects on topical hypotensive medication: 42-month outcomes. ( 29440867 )
2018
41
Factors associated with developing a fear of falling in subjects with primary open-angle glaucoma. ( 29433472 )
2018
42
Screening for Primary Open-angle Glaucoma (POAG). ( 29870406 )
2018
43
Risk of obstructive sleep apnea in open-angle glaucoma versus controls using the STOP-Bang questionnaire. ( 29426446 )
2018
44
Latanoprostene Bunod Ophthalmic Solution 0.024%: A Review in Open-Angle Glaucoma and Ocular Hypertension. ( 29761382 )
2018
45
Baseline Lamina Cribrosa Curvature and Subsequent Visual Field Progression Rate in Primary Open-Angle Glaucoma. ( 29945800 )
2018
46
Latanoprostene Bunod 0.024% in Subjects With Open-angle Glaucoma or Ocular Hypertension: Pooled Phase 3 Study Findings. ( 29194198 )
2018
47
A multiethnic genome-wide association study of primary open-angle glaucoma identifies novel risk loci. ( 29891935 )
2018
48
Role of CYP1B1, p.E229K and p.R368H mutations among 120 families with sporadic juvenile onset open-angle glaucoma. ( 29168043 )
2018
49
Testosterone Pathway Genetic Polymorphisms in Relation to Primary Open-Angle Glaucoma: An Analysis in Two Large Datasets. ( 29392307 )
2018
50
Efficacy of three different formulations of brimonidine for control of intraocular pressure in primary open-angle glaucoma: A 6-week randomized trial. ( 29930448 )
2018
Sources

Variations for Open-Angle Glaucoma

About this section
Sources

Expression for Open-Angle Glaucoma

About this section
Search GEO for disease gene expression data for Open-Angle Glaucoma.
Sources

Pathways for Open-Angle Glaucoma

About this section

Pathways related to Open-Angle Glaucoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Degradation of the extracellular matrix 66
Show member pathways
 12.09 ELN LOXL1 LTBP2 MMP1 OPTC TGFB2
2
Fluid shear stress and atherosclerosis 37
11.58 CAV2 GSTM1 GSTT1
3
Elastic fibre formation 66
Show member pathways
 10.79 ELN LOXL1 LTBP2 TGFB2
4
Naphthalene metabolism 22
10.54 GSTM1 GSTT1
Sources

GO Terms for Open-Angle Glaucoma

About this section

Cellular components related to Open-Angle Glaucoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular matrix GO:0031012 9.1 ELN LOXL1 LTBP2 MMP1 MYOC TGFB2

Biological processes related to Open-Angle Glaucoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular matrix disassembly GO:0022617 9.33 ELN MMP1 OPTC
2 glutathione derivative biosynthetic process GO:1901687 9.26 GSTM1 GSTT1
3 positive regulation of xenophagy GO:1904417 8.96 OPTN TBK1
4 collagen fibril organization GO:0030199 8.8 CYP1B1 LOXL1 TGFB2
Sources

Sources for Open-Angle Glaucoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....